Rodman & Renshaw Global Healthcare Conference 2008 Presenter Profiles

16/05/2008 - 12:30

Rodman & Renshaw Global Healthcare Conference 2008 takes place May

19-20, 2008 at the Le Meridien Beach Plaza Hotel, in Monte Carlo

Monaco. In-depth information about the event is available at http://www.rodmanandrenshaw.com/conferences?id=18&link=confinfo.
Business Wire is the official news wire for the Rodman & Renshaw Global

Healthcare Conference. Listed below are profiles from the conference

presenters. Breaking news releases and photos are available at http://www.tradeshownews.com

Business Wire´s trade show, conference, and event news resource.

= = = = = = = = = = =

Company:

Access Pharmaceuticals, Inc.

- - - - - -

Ticker Symbol & Exchange:
ACCP.OB
- - - - - -

Investor Relations Contact:
Stephen B. Thompson
- - - - - -

Investor Relations Contact Phone:
214-905-5100
- - - - - -

Web:
www.accesspharma.com
- - - - - -

Date of Presentation:
Monday, May 19, 2008
- - - - - -

- - - - - -

Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical

company focused on the development and commercialization of

proprietary products for the treatment and supportive care of cancer

patients. Access has one approved product, MuGard? for the management of oral mucositis. The company´s

lead oncology product is ProLindacâ„¢

polymer-linked platinum cancer drug, which is in Phase 2 clinical

testing in recurrent ovarian cancer patients. Angiolix®

an antiangiogenic humanized monoclonal antibody, and Prodrax®

a hypoxia-activated prodrug, are the company´s

lead preclinical oncology products. Access is also developing oral

insulin and oral hGH using its proprietary Cobalaminâ„¢ oral drug delivery technology.
- - - - - -

- - - - - -

Company:
Active Biotech AB
- - - - - -

Ticker Symbol & Exchange:
ACTI OMX Nordic
- - - - - -

Investor Relations Contact:
Göran Forsberg
- - - - - -

Investor Relations Contact Phone:
46 46 19 11 54
- - - - - -

Web:
www.activebiotech.com
- - - - - -

Date of Presentation:
20-May
- - - - - -

- - - - - -

Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company

focusing on research and development of pharmaceuticals. Active

Biotech has a strong R&D portfolio with pipeline products focused on

autoimmune/inflammatory diseases and cancer. Most advanced projects

are laquinimod, an orally administered small molecule with unique

immunomodulatory properties for the treatment of multiple sclerosis

as well as ANYARA for use in cancer targeted therapy, primarily

renal cancer. Further key projects in clinical development comprise

the three orally administered compounds TASQ for prostate cancer

57-57 for SLE and RhuDex® for RA.
- - - - - -

- - - - - -

Company:
Addex Pharma SA
- - - - - -

Ticker Symbol & Exchange:
ADXN
- - - - - -

Investor Relations Contact:
Chris Maggos
- - - - - -

Investor Relations Contact Phone:
41 22 884 15 11
- - - - - -

Web:
www.addexpharma.com
- - - - - -

Date of Presentation:
20/05/2008
- - - - - -

- - - - - -

Addex Pharmaceuticals Ltd discovers and develops allosteric

modulators, an emerging class of small molecule therapeutic agents.

Allosteric modulation may offer more sophisticated ways to normalize

biological signaling compared to classical orthosteric agonist or

antagonist drugs.
- - - - - -

- - - - - -

Lead product, ADX10059, a negative allosteric modulator (NAM) of

metabotropic glutamate receptor 5 (mGluR5), showed clinically and

statistically significant efficacy in separate Phase IIa clinical

trials in gastroesophageal reflux disease (GERD) and migraine. The

company has 12 early stage products.
- - - - - -

- - - - - -

The Addex allosteric modulation discovery and development platform

has been additionally validated through product collaborations with

Merck & Co., Inc. and Johnson & Johnson.
- - - - - -

- - - - - -

Company:
Biosante Pharmaceuticals, Inc.
- - - - - -

Ticker Symbol & Exchange:
BPAX/NASDAQ
- - - - - -

Investor Relations Contact:
Phillip Donenberg
- - - - - -

Investor Relations Contact Phone:
847-478-0500 ext 100
- - - - - -

Web:
www.biosantepharma.com
- - - - - -

Date of Presentation:
19-May-08
- - - - - -

- - - - - -

BioSante is a specialty pharmaceutical company focused on developing

products for female sexual health, menopause, contraception and male

hypogonadism. BioSante´s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by

BioSante under a U.S. Food and Drug Administration (FDA) SPA

(Special Protocol Assessment) for the treatment of female sexual

dysfunction (FSD), and Elestrinâ„¢ (estradiol gel) developed through FDA approval by BioSante

indicated for the treatment of moderate-to-severe vasomotor symptoms

associated with menopause, currently marketed in the U.S. Also in

development are Bio-T-Gelâ„¢

testosterone gel for male hypogonadism, and an oral contraceptive in

Phase II clinical development using BioSante patented technology.
- - - - - -

- - - - - -

Company:
Cyclacel Pharmaceuticals, Inc.
- - - - - -

Ticker Symbol & Exchange:
CYCC
- - - - - -

Investor Relations Contact:
Corey Sohmer
- - - - - -

Investor Relations Contact Phone:
1 908 517 7330
- - - - - -

Web:
www.cyclacel.com
- - - - - -

Date of Presentation:
May 20th
- - - - - -

- - - - - -

Cyclacel is a diversified biopharmaceutical business dedicated to

the discovery, development and commercialization of novel, targeted

drugs to treat cancer. Cyclacel´s

strategy is focused on leading edge therapeutic management of cancer

patients based on a portfolio of three medicines marketed by its

ALIGN subsidiary and a deep development pipeline. Three

orally-available drugs are in clinical development: sapacitabine (in

two randomized Phase 2 studies for the treatment of elderly acute

myeloid leukemia and cutaneous T-cell lymphoma); seliciclib (in two

randomized Phase 2 studies for the treatment of lung and

nasopharyngeal cancers) and CYC116 (in Phase 1 in patients with

solid tumors).
- - - - - -

- - - - - -

Company:
Cytori Therapeutics
- - - - - -

Ticker Symbol & Exchange:
CYTX
- - - - - -

Investor Relations Contact:
Tom Baker
- - - - - -

Investor Relations Contact Phone:
858.458.0900
- - - - - -

Web:
www.cytoritx.com
- - - - - -

Date of Presentation:
5.19.08
- - - - - -

- - - - - -

Cytori Therapeutics´ (NASDAQ:CYTX) goal is to be the global leader

in regenerative medicine. The company is dedicated to providing

patients with new options for reconstructive surgery, developing

treatments for cardiovascular disease, and banking patients´ adult

stem and regenerative cells. The Celution® 800 System is being introduced in Europe into the reconstructive

surgery market while the Celutionâ„¢ 900

System will be launched in Asia-Pacific for cryopreserving a

patient´s own stem and regenerative cells. Clinical trials are

ongoing in cardiovascular disease and planned for spinal disc

degeneration, gastrointestinal disorders, and other unmet medical

needs. www.cytoritx.com
- - - - - -

- - - - - -

Company:
DOV Pharmaceutical, Inc.
- - - - - -

Ticker Symbol & Exchange:
DOVP.OB
- - - - - -

Investor Relations Contact:
Barbara Duncan
- - - - - -

Investor Relations Contact Phone:
732-907-3604
- - - - - -

Web:
www.dovpharm.com
- - - - - -

Date of Presentation:
19-May-08
- - - - - -

- - - - - -

DOV is a biopharmaceutical company focused on the development of

novel product candidates for disorders of the central nervous

system, or CNS. We currently have drug development programs that

are at the preclinical, Phase I and Phase II clinical stages

including DOV 21, 947 (in a Phase II clinical trial for

depression), DOV 102,677 (which has completed a Phase I clinical

trial) and a preclinical discovery program in reuptake inhibitors

and GABA modulators.

- - - - - -

Company:
Evotec AG
- - - - - -

Ticker Symbol & Exchange:
FSE:EVT, NASDAQ:EVTC
- - - - - -

Investor Relations Contact:
Anne Hennecke
- - - - - -

Investor Relations Contact Phone:
49-40-56081-286
- - - - - -

Web:
www.evotec.com
- - - - - -

Date of Presentation:
May 20, 2008, 11.00 am CET
- - - - - -

- - - - - -

Evotec is a leader in the discovery and development of novel small

molecule drugs. In proprietary projects, Evotec specializes in

finding new treatments for diseases of the CNS. Evotec has 3

programs in clinical development: EVT201, a partial positive

allosteric modulator of the GABA-A receptor complex for the

treatment of insomnia, EVT101, a subtype selective NMDA receptor

antagonist for the treatment of Alzheimer´s disease and/or pain, and

EVT302, a MAO-B inhibitor in development for smoking cessation.

Evotec´s proprietary preclinical research programs focus on the

purinergic receptors, P2X3 and P2X7, for the potential treatment of

pain and inflammatory diseases. In addition, Evotec has worldwide

collaboration and license agreements with Pfizer to research

develop and commercialize small molecule vanilloid receptor (VR1)

antagonists.
- - - - - -

- - - - - -

Company:
FIBREX MEDICAL Inc.
- - - - - -

Investor Relations Contact:
Rainer Henning, President & CE
- - - - - -

Investor Relations Contact Phone:
43-1-86634-9270
- - - - - -

Web:
www.fibrexmedical.com
- - - - - -

Date of Presentation:
20-May
- - - - - -

- - - - - -

FIBREX MEDICAL is a development stage biopharmaceutical company

with operations in Vienna/Austria. The company mission is to

develop and commercialize innovative therapeutics in the fields of

cardiovascular diseases and inflammation. FIBREX MEDICAL is

discovering and developing peptides and peptide analogs with

anti-inflammatory and endothelial protectant activity. Lead

compound FX06MRI is under clinical evaluation for the treatment of

reperfusion injury after myocardial infarction via a novel

mechanism of action.

- - - - - -

Company:
Genetic Imunity
- - - - - -

Investor Relations Contact:
Dr. Julianna Lisziewicz ; Dr. Zsolt Lisziewicz
- - - - - -

Investor Relations Contact Phone:
36-302-116402
- - - - - -

Web:
www.geneticimmunity.com
- - - - - -

Date of Presentation:
May 19: from 09:20 to 09:40 AM
- - - - - -

- - - - - -

Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical

company focused on the discovery, development and commercialization

of topically administered Nanomedicines for targeted immune

amplification. The Company´s Nanomedicine

platform focuses on significant unmet medical needs such as

infectious diseases, cancer and allergies. The DermaVir Patch

Genetic Immunity´s lead Nanomedicine candidate, is in Phase II

clinical development and could be the first Nanomedicine approved

for HIV/AIDS. Phase I/II trials to date of the DermaVir Patch have

confirmed safety and tolerability and the amplification of

HIV-specific T cell precursors (PHPC), which correlate with

decreased viral load (Caralota et al, J Immunol 2008).
- - - - - -

- - - - - -

Company:
GTC Biotherapeutics
- - - - - -

Ticker Symbol & Exchange:
GTCB NASDAQ
- - - - - -

Investor Relations Contact:
Thomas Newberry
- - - - - -

Investor Relations Contact Phone:
508-370-5374
- - - - - -

Web:
www.gtc-bio.com
- - - - - -

Date of Presentation:
20-May-08
- - - - - -

- - - - - -

GTC Biotherapeutics develops, produces, and commercializes

therapeutic proteins through transgenic animal technology. ATryn®

GTC´s recombinant form of human

antithrombin, is approved by the European Commission for use in

patients with hereditary antithrombin deficiency undergoing surgical

procedures. This was the first approval anywhere in the world of a

therapeutic protein produced from a transgenic animal. GTC´s

transgenic production platform is particularly well suited to

enabling cost effective development of proteins that are difficult

to express in traditional recombinant production systems as well as

those that are required in large volumes at a competitive cost.

Additional information is at http://www.gtc-bio.com.
- - - - - -

- - - - - -

Company:
Haemacure
- - - - - -

Ticker Symbol & Exchange:
HAE: TSX
- - - - - -

Investor Relations Contact:
Joseph Galli - 1.514.990.7074
- - - - - -

Investor Relations Contact Phone:
Diane Roch - 514.282.3350 x27
- - - - - -

Web:
www.haemacure.com
- - - - - -

Date of Presentation:
May 20 at 1:40p.m. - Zephir Room
- - - - - -

- - - - - -

Haemacure is a specialty biotherapeutics company developing

high-value human plasma-derived protein products for

commercialization. Haemacure´s research and development effort is

driven by its proprietary plasma protein extraction technology to

develop next-generation products, including surgical hemostats.

Haemacure´s lead product candidate, Hemaseel®HMN

is a fibrin sealant planned to enter pivotal Phase II/Phase III

clinical trials during the first quarter of 2009. Haemacure´s second

product candidate is thrombin, a component of its fibrin sealant

now in preclinical stage. Follow-on development will focus on

surgical hemostats, wound healing, adhesion prevention, regenerative

medecine, drug delivery and combination with biomaterials.

Additional information available on www.haemacure.com.
- - - - - -

- - - - - -

Company:
Helsinn Healthcare SA
- - - - - -

Investor Relations Contact:
Alessandro Bossi
- - - - - -

Investor Relations Contact Phone:
41 (0) 91 9852121 41 (0) 79 5084705
- - - - - -

Web:
www.helsinn.com
- - - - - -

Date of Presentation:
May 19, 2008 12:30pm (10:30am GMT)
- - - - - -

- - - - - -

Helsinn Healthcare SA announced today that Mr.Riccardo Braglia, CEO

will present an overview of the company, its products and corporate

goals at the Rodman & Renshaw Global Healthcare Conference, Monte

Carlo, Monaco on May 19th 2008 at 12:30pm (10:30am GMT). The

presentation will be webcast live and can be accessed by logging on

to the web site (www.wsw.com/webcast/rrshq13/helsinn). An archived

version is available for 90 days.
- - - - - -

- - - - - -

Helsinn (www.helsinn.com) is a privately owned Swiss-based

pharmaceutical group. Core business: pain, inflammation, oncology

and supportive care. Business strategy: in-license early stage new

chemical entities, complete their development up to market approvals

and out-license to its worldwide network of partners. The active

pharmaceutical ingredients and drug products are manufactured at

Helsinn´s cGMP facilities.
- - - - - -

- - - - - -

Company:
Hythiam, Inc.
- - - - - -

Ticker Symbol & Exchange:
HYTM: NASDAQ
- - - - - -

Investor Relations Contact:
Lisa Wilson
- - - - - -

Investor Relations Contact Phone:
In-Site Communications, Inc., 212-759-3929
- - - - - -

Web:
www.hythiam.com
- - - - - -

Date of Presentation:
Monday, May 19, 2008 at 5:15 pm
- - - - - -

- - - - - -

Hythiam, Inc. provides behavioral health management services to

health plans, employers, criminal justice, and government agencies

through a network of licensed and company managed healthcare

providers. Hythiam approaches the management of behavioral health

disorders with a focus on using the latest medical and health

technology aimed towards improved outcomes and out-patient

treatment. Hythiam offers disease management for substance

dependence built around its patented PROMETA Treatment Program for

alcoholism and dependence to stimulants. Hythiam also researches

develops, licenses and commercializes innovative and proprietary

physiological, nutritional, and behavioral treatment programs.
- - - - - -

- - - - - -

Company:
Inovio Biomedical
- - - - - -

Ticker Symbol & Exchange:
INO
- - - - - -

Investor Relations Contact:
Bernie Hertel
- - - - - -

Investor Relations Contact Phone:
858 410-3101
- - - - - -

Web:
www.inovio.com
- - - - - -

Date of Presentation:
19-May-08
- - - - - -

- - - - - -

Inovio Biomedical (AMEX: INO) is focused on developing multiple

DNA-based immunotherapies and DNA vaccines. Inovio is a leader in

developing human applications of electroporation, using brief

controlled electrical pulses to increase cellular uptake of a useful

biopharmaceutical. Human data has shown that Inovio´s

electroporation-based DNA delivery technology can significantly

increase gene expression and immune responses from DNA vaccines.

Immunotherapy partners include Merck, Wyeth, Vical, University of

Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer

Institute, and International Aids Vaccine Initiative. Inovio´s

technology is protected by an extensive patent portfolio covering in

vivo electroporation.
- - - - - -

- - - - - -

Company:
Interleukin Genetics, Inc.
- - - - - -

Ticker Symbol & Exchange:
AMEX: ILI
- - - - - -

Investor Relations Contact:
Melanie Friedman
- - - - - -

Investor Relations Contact Phone:
212-362-1200
- - - - - -

Web:
http://www.ilgenetics.com
- - - - - -

Date of Presentation:
19-May-08
- - - - - -

- - - - - -

Interleukin Genetics is a science-based personalized health company

using applied genetics to empower consumers to improve their health.

Interleukin is studying the role of inflammatory genes in diseases

of aging and has commercialized the PST® Periodontal genetic test, the Gensona® IL-1 Cardiovascular genetic test and the Gensona® General Nutrition genetic test. In addition to launching its own

tests, Interleukin aims to partner with biotechnology and

pharmaceutical companies to develop molecular diagnostics.

Interleukin is also developing genetic tests to address health risks

for osteoporosis, obesity, arthritis and cancer and sells an array

of Nutraceuticals through some of the nation´s

largest retailers.
- - - - - -

- - - - - -

Company:
Lev Pharmaceuticals, Inc.
- - - - - -

Ticker Symbol & Exchange:
LEVP
- - - - - -

Investor Relations Contact:
Jason Tuthill
- - - - - -

Investor Relations Contact Phone:
212-850-9130
- - - - - -

Web:
www.levpharma.com
- - - - - -

Date of Presentation:
5/20/2008
- - - - - -

- - - - - -

Lev is a biopharmaceutical company focused on developing and

commercializing therapeutic products for the treatment of

inflammatory diseases. Lev´s lead product

candidate, Cinryzeâ„¢ (C1 inhibitor), is

being developed as a replacement therapy for both the acute and

prophylactic treatment of hereditary angioedema (HAE), also known as

C1 inhibitor deficiency. Cinryzeâ„¢ has

been granted orphan drug status for the acute and prophylactic

treatment of HAE, potentially securing, upon approval, market

exclusivity for seven years. Additionally, Lev is in the process of

prioritizing its C1 inhibitor development platform for the treatment

of selective other diseases and disorders in which inflammation is

known or believed to play an underlying role.
- - - - - -

- - - - - -

Company:
Maxygen
- - - - - -

Ticker Symbol & Exchange:
Nasdaq: MAXY
- - - - - -

Investor Relations Contact:
Michele Boudreau
- - - - - -

Investor Relations Contact Phone:
650-297-2088
- - - - - -

Web:
www.maxygen.com
- - - - - -

Date of Presentation:
19-May-08
- - - - - -

- - - - - -

Maxygen is a biopharmaceutical company focused on developing

improved versions of protein drugs. The company´s

lead program, MAXY-G34, is designed to be an improved long-acting

G-CSF for the treatment of neutropenia. MAXY-G34 is currently in

Phase II clinical trials. Also in Maxygen´s

pipeline is a new Factor VIIa product candidate for the treatment of

hemophilia and new CTLA4-Ig product candidates for the treatment of

rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling

technology and extensive protein modification expertise to pursue

the creation of biosuperior proteins.
- - - - - -

- - - - - -

Company:
Neotropix, Inc.
- - - - - -

Investor Relations Contact:
Peter Lanciano, CEO; Planciano@neotropix.com
- - - - - -

Investor Relations Contact Phone:
617-460-1200
- - - - - -

Web:
www.neotropix.com
- - - - - -

Date of Presentation:
20-May-08
- - - - - -

- - - - - -

Neotropix develops several cancer drugs using a proprietary and

innovative platform sourcing natural products that selectively

bind to cancer cells and naturally kill through lysis.

- - - - - -

The lead product NTX-010 is a highly selective drug that

specifically treats carcinoid, small cell and several pediatric

neuroendocrine cancers. NTX-010 is currently completing enrollment

in a large carcinoid trial. Data demonstrates the ability of

NTX-010 to obtain significant clinical effect as compared to the

control group in each of time-to-progression, reduction in tumors

and key biochemical markers. The clincal study is being conducted

at multiple USA centers including John Hopkins, USO, Mt Sinai and

Mary Crowley Cancer Research Center.

- - - - - -

Company:
Novelos Therapeutics, Inc.
- - - - - -

Ticker Symbol & Exchange:
OTCBB: NVLT
- - - - - -

Investor Relations Contact:
Stephen Lichaw
- - - - - -

Investor Relations Contact Phone:
201-240-3200
- - - - - -

Web:
www.novelos.com
- - - - - -

Date of Presentation:
May 19, 2008, 2:30pm
- - - - - -

- - - - - -

Novelos Therapeutics, Inc. is a biopharmaceutical company

commercializing oxidized glutathione-based compounds for the

treatment of cancer and hepatitis. NOV-002, the lead compound

currently in Phase 3 development for lung cancer under SPA and Fast

Track, acts together with chemotherapy as a chemoprotectant and a

chemopotentiator. NOV-002 is also in Phase 2 development for

chemotherapy-resistant ovarian cancer and early-stage breast cancer.

NOV-205 acts as a hepatoprotective agent with immunomodulating and

anti-inflammatory properties. NOV-205 is in Phase 1b development for

chronic hepatitis C non-responders. Both compounds have completed

clinical trials in humans and have been approved for use in the

Russian Federation where they were originally developed.
- - - - - -

- - - - - -

Company:
Osteologix, Inc.
- - - - - -

Ticker Symbol & Exchange:
OLGX.OB
- - - - - -

Investor Relations Contact:
Baxter Phillips, III
- - - - - -

Investor Relations Contact Phone:
804.754.6970
- - - - - -

Web:
www.osteologix.com
- - - - - -

Date of Presentation:
Monday, May 19
- - - - - -

- - - - - -

Osteologix is a specialty pharmaceutical company committed to

developing innovative therapies for the treatment and prevention of

musculoskeletal diseases. It is our vision to improve the health of

those afflicted with musculoskeletal diseases such as osteoporosis.

We partner with the healthcare community to apply new scientific

information and clinical data to the development of products that

improve patient care in a safe and ethical manner. Osteologix´s

lead product candidate, NB S101, is a novel pharmaceutical agent for

the treatment and prevention of osteoporosis.
- - - - - -

- - - - - -

Company:
Pluristem Therapeutics Inc.
- - - - - -

Ticker Symbol & Exchange:
NASDAQ:PSTI; DAX:PJT
- - - - - -

Investor Relations Contact:
William Prather RPh, MD
- - - - - -

Investor Relations Contact Phone:
1-303-883-4954
- - - - - -

Web:
www.pluristem.com
- - - - - -

Date of Presentation:
20 May 2008 at 9:00 a.m.
- - - - - -

- - - - - -

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated

to the commercialization of non-personalized (allogeneic) cell

therapy products targeting Peripheral Artery Disease (PAD), as well

as Bone Marrow Transplantation (BMT), ischemic stroke, Multiple

Sclerosis and additional autoimmune disorders, such as Crohn´s

disease. The Company´s product candidates are derived from the human

placenta, a non-controversial, non-embryonic, adult stem cell source

and are stored ready-to-use. The placental cells are expanded in the

Company´s proprietary PluriXâ„¢ 3D bioreactor and are termed PLX (PLacental eXpanded) cells.

Pluristem´s products have the potential

to participate in the approximate $30B therapeutic and regenerative

cellular market.
- - - - - -

- - - - - -

Company:
Synvista Therapeutics
- - - - - -

Ticker Symbol & Exchange:
AMEX: SYI
- - - - - -

Investor Relations Contact:
Kim Golodetz, LHA
- - - - - -

Investor Relations Contact Phone:
212-838-3777
- - - - - -

Date of Presentation:
19-May-08
- - - - - -

- - - - - -

Synvista Therapeutics is a biopharmaceutical company developing

drugs and diagnostics for cardiovascular disease and nephropathy in

diabetics. The Company´s portfolio includes orally bioavailable

organoselenium mimics of glutathione peroxidase, one of which is in

Phase 2, which metabolizes lipid peroxides and has the potential to

limit myocardial damage subsequent to myocardial infarction. It is

also developing alagebrium, a breaker of AGEs, currently in Phase 2

for treatment of heart failure. The Company is also developing

several clinical diagnostic tests, among them one for cardiovascular

risk assessment, using Haptoglobin characterization, to identify

patients at high risk for cardiovascular complications of diabetes.
- - - - - -

- - - - - -

Company:
TopoTarget A/S
- - - - - -

Ticker Symbol & Exchange:
OMX: TOPO
- - - - - -

Investor Relations Contact:
Rachel Curtis Gravesen

- - - - - -

Investor Relations Contact Phone:
45 25 12 62 60
- - - - - -

Web:
www.topotarget.com
- - - - - -

Date of Presentation:
20-May-08
- - - - - -

- - - - - -

TopoTarget is a dynamic international biotech company dedicated to

finding "Answers for cancer."

- - - - - -

Founded by clinicians with a thorough knowledge of the molecular

mechanisms of cancer, our goal is to find and develop cancer

therapies, bringing them to the market to benefit patients. We have

top class experts in clinical development, regulatory and

pre-clinical departments.
- - - - - -

- - - - - -

TopoTarget´s lead product belinostat is due to begin a pivotal trial

in the second half of 2008 and we have a further 8 products in

clinical development. Using our own highly specialised dedicated

sales team, we launched our first marketed product, Savene®/Totect® in Europe/US in 2006 and 2007 respectively. Savene®/Totect® is used for the treatment of anthracycline extravasation, an

accident that can occur during chemotherapy.
- - - - - -

- - - - - -

Company:
Transdel Pharmaceuticals, Inc.
- - - - - -

Ticker Symbol & Exchange:
OTCBB: TDLP
- - - - - -

Investor Relations Contact:
John Lomoro, CFO; johnl@transdelpharma.com
- - - - - -

Investor Relations Contact Phone:
858-457-5300
- - - - - -

Web:
www.transdelpharma.com
- - - - - -

Date of Presentation:
May 19, 2008, 4:35 pm local time
- - - - - -

- - - - - -

Specialty pharmaceutical company focused on the development and

commercialization of non-invasive topically delivered medications.

The Company´s innovative patented proprietary Transdelâ„¢ cream formulation technology is designed to facilitate the effective

penetration of drugs through the tough skin barrier to reach the

target underlying tissues. In the case of Ketotransdelâ„¢

the Transdelâ„¢ cream allows the active

ingredient ketoprofen to reach the target soft tissue and exert its

well-known localized anti-inflammatory and analgesic effects. The

Company is also investigating other drug candidates and treatments

for transdermal delivery using the patented Transdelâ„¢ platform technology for products in pain management and other

therapeutic areas.
- - - - - -

Note to Editors: Business Wire´s PressPass allows you to create

free, custom Web, RSS, and email-based news feeds from more than 160

industry options, dozens of subject categories and thousands of

geographic preferences as well as by specific company filters. In

addition, PressPass subscribers have access to exclusive content

experts, company profiles, email alerts, survey services and other media

services.
Note to Event Organizers: Add your trade show, conference, or

event to http://www.tradeshownews.com

Business Wire´s online event calendar. For information, email tradeshow

(at) businesswire.com.